Ascentage Pharma Group International has recently announced the submission of a new drug application for lisaftoclax in China, marking a significant milestone in the program's progress. This novel Bcl-2 inhibitor has demonstrated antitumor activity in both previously untreated patients and those treated with venetoclax, addressing critical treatment gaps in difficult-to-treat myeloid malignancies. If approved, lisaftoclax would be the second Bcl-2 inhibitor to receive approval globally. This regulatory submission underscores Ascentage Pharma's commitment to developing innovative therapies for patients with limited treatment options.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.